Evidence map›Paper›PMID 25197811›Full record

ArticleSleep2014

Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening.

Patricia Rubio-Sastre, Frank A J L Scheer, Purificación Gómez-Abellán, Juan A Madrid, Marta Garaulet

Open access · bronzeAbstract readControlled Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Article in Sleep, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 5 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 5 syntheses or guidelines pooled it, 172 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Endogenous circadian system and circadian misalignment impact glucose tolerance via separate mechanisms in humans.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Trial
  17. Review
  18. Nocturnal melatonin secretion and risk of type 2 diabetes: a prospective cohort study.The Journal of clinical endocrinology and metabolism · 2026
    Article
  19. Article
  20. Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Patricia Rubio-SastreDepartment of Physiology, University of Murcia, IMIB-Arrixaca, Murcia, Spain.
Frank A J L ScheerDivision of Sleep and Circadian Disorders, Brigham and Women's Hospital, and Division of Sleep Medicine, Harvard Medical School, Boston, MA.
Purificación Gómez-AbellánDepartment of Physiology, University of Murcia, IMIB-Arrixaca, Murcia, Spain.
Juan A MadridDepartment of Physiology, University of Murcia, IMIB-Arrixaca, Murcia, Spain.
Marta GarauletDepartment of Physiology, University of Murcia, IMIB-Arrixaca, Murcia, Spain.
Universidad de Murcia · ESCircadian (United States) · US

Funding

Mechanisms underlying adverse health consequences of shift workR01HL094806 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHEER, FRANK A · 2009 to 2013
$1.6M
NHLBI NIH HHS R01 HL094806
6 · The paper itself

Abstract

STUDY

objectivesTo study the effect of melatonin administration on glucose metabolism in humans in the morning and evening.

designPlacebo-controlled, single-blind design.

settingLaboratory assessments.

participants21 healthy women (24 ± 6 y; body mass index: 23.0 ± 3.3 kg/m(2)).

interventionsGlucose tolerance was assessed by oral glucose tolerance tests (OGTT; 75 g glucose) on 4 occasions: in the morning (9 AM), and evening (9 PM); each occurring 15 minutes after melatonin (5 mg) and placebo administration on 4 non-consecutive days. MEASUREMENTS AND

resultsMelatonin administration impaired glucose tolerance. When administered in the morning, melatonin significantly increased the incremental area under the curve (AUC) and maximum concentration (Cmax) of plasma glucose following OGTT by 186% and 21%, respectively, as compared to placebo; while in the evening, melatonin significantly increased glucose AUC and Cmax by 54% and 27%, respectively. The effect of melatonin on the insulin response to the OGTT depended on the time of day (P < 0.05). In the morning, melatonin decreased glucose tolerance primarily by decreasing insulin release, while in the evening, by decreasing insulin sensitivity.

conclusionsAcute melatonin administration in humans impairs glucose tolerance in both the morning and evening. When administering melatonin, the proximity to meal timing may need to be considered, particularly in those at risk for glucose intolerance.

Indexed as

AdultArea Under CurveBlood GlucoseBody Mass IndexFemaleGlucose IntoleranceGlucose Tolerance TestHumansInsulinInsulin ResistanceInsulin SecretionMelatoninSingle-Blind MethodTime FactorsYoung AdultBlood GlucoseInsulinMelatoninglucose toleranceinsulin resistancemelatoninmetabolic syndromeoral glucose tolerance test

Identifiers

PMID25197811
PMCPMC4173928
OpenAlexW2082407123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.